Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,540.00
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
-0.54%
)
Bitcoin
77,370.43
(
-1.16%
)
News Focus
News Focus
Post# of 257443
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122886
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 192651

Tuesday, 03/14/2017 11:00:52 AM

Tuesday, March 14, 2017 11:00:52 AM

Post# of 257443
AGN CEO admits that Kybella—the double-chin drug—has fallen far short of commercial expectations. On today's Barclays webcast, Brent Saunders said that many Kybella patients have so much swelling and redness they never return for a second injection, and hence they don't show much cosmetic benefit from the single treatment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today